Intercept Pharmaceuticals Inc. | Key People and Executives
Mark E. Pruzanski
President, Chief Executive Officer & Director
Gino Santini
Lead Independent Director
Srinivas Akkaraju
Independent Director
Nancy Miller-Rich
Independent Director
Keith M. Gottesdiener
Independent Director
Daniel Mark Bradbury
Independent Director
Daniel G. Welch
Independent Director
Luca Benatti
Independent Director
Glenn P. Sblendorio
Independent Director
Mark E. Pruzanski
President, Chief Executive Officer & Director
Jerome B. Durso
Chief Operating Officer
Sandip S. Kapadia
CFO, Treasurer & Principal Accounting Officer
Christian Weyer
Executive Vice President-Research & Development
David A. Shapiro
Chief Medical Officer
Richard Kim
Senior Vice President-Commercial Head of US
Juan Carlos Lopez-Talavera
Senior Vice President-Head Medical Affairs
Lisa Bright
President-International
Christopher Frates
Media Contact
Mark J. Vignola
Director-Investor Relations
David Ford
Chief Human Resources Officer
Ryan T. Sullivan
Secretary & General Counsel
Gino Santini
Lead Independent Director
Srinivas Akkaraju
Independent Director
Nancy Miller-Rich
Independent Director
Keith M. Gottesdiener
Independent Director
Daniel Mark Bradbury
Independent Director
Daniel G. Welch
Independent Director
Luca Benatti
Independent Director
Glenn P. Sblendorio
Independent Director
| Address |
10 Hudson Yards
New York New York 10001
United States
|
|
Employees
|
- |
| Website |
http://www.interceptpharma.com |
| Updated |
07/08/2019 |
| Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. |
